Reovirus type 3 Dearing has demonstrated oncolytic efficacy in vitro and in vivo against a variety of cancer cell lines, tumor xenografts and syngeneic cancer models. In this study, we investigated the effectiveness of reovirus against aberrant crypt foci (ACF) and colon cancer induced by the carcinogen azoxymethane (AOM) in an immunocompetent rat model. Sprague-Dawley rats received 15 mg/kg AOM intraperitoneally once per week for 4 weeks and reovirus was administered rectally once a week for 5 weeks starting 20 weeks after the last dose of AOM. Two weeks after completion of reovirus therapy, animals were examined for tumor burden in the colon and other tissues. Reovirus-treated animals showed a decrease in total ACF numbers (P ¼ 0.014), in large ACFs (P ¼ 0.0069) and in tumor number (P ¼ 0.03) compared to vehicle-treated animals. Fewer obstructing tumors in the colon (P ¼ 0.07) and duodenum (P ¼ 0.03) and reduced hepatic metastases were also noted. In addition, a tumor cell line derived from hepatic metastases was found to be susceptible to reovirus in vitro. Our results show that repeated rectal reovirus administration had some efficacy in the treatment and prevention of AOM-induced ACFs, colon cancers and metastases.
Introduction
Each year, over 150 000 new cases of colorectal cancer (CRC) are diagnosed in North America and about onethird of patients die from it. The highest incidence rates occur in developed countries where it is often the second leading cause of cancer-related deaths, behind lung cancer. In the United States, roughly 6% of individuals develop invasive CRCs in their lifetimes, with similar ratios in Europe. 1, 2 Treatment generally consists of a combination of surgical resection, radiation and chemotherapy, but for patients with metastatic disease, the prognosis is poor. Substantial therapeutic improvement is still needed in the medical (non-surgical) management of these malignancies.
Reovirus, a benign double-stranded RNA virus of the human respiratory and gastrointestinal tract, has been extensively investigated as a potential novel anticancer therapy. It has shown to infect and lyse many cancer cell types while leaving untransformed cells relatively unaffected. [3] [4] [5] Clinical trials using reovirus as a cancer therapeutic are currently ongoing and the phase I and II trials performed with patients bearing subcutaneous carcinomas, prostate carcinomas and glioblastomas so far have indicated the safety of this viral treatment and have provided some evidence of efficacy (www.oncolyticsbiotech.com).
Colorectal malignancies should represent a good target for reoviral oncolytic therapy. Reovirus naturally infects the gastrointestinal tract of humans and many cases of aberrant crypt foci (ACF) and colon carcinomas bear elevated proteolytic activity and activating mutations of the proto-oncogene ras, both of which can enhance reovirus susceptibility. 3, [6] [7] [8] So far, reovirus has been shown to infect efficiently several human colon cancer cell lines in vitro and to inhibit growth of implanted tumors in severely combined immunodeficient mice by either intratumoral or intravenous injection. 4 Furthermore, reovirus demonstrated therapeutic effect against syngeneic C26 colorectal liver metastases in BALB/c mice when used in conjunction with the immunosuppressive drug cyclosporin A. 9 Nonetheless, these in vivo studies relied on injection of established cancer cells into mice and do not fully reflect the program of development, progression and metastasis of human colon malignancies.
We aimed to investigate the effect of reovirus at earlier stages of oncogenesis as well as once the disease is well established. To address this, we chose a rat model of CRC whereby Sprague-Dawley rats are administered the potent carcinogen azoxymethane (AOM) and subsequently develop a high number of neoplastic lesions. 10 We found that repeated rectal administration of reovirus demonstrated signs of efficacy in the treatment and prevention of AOM-induced ACF, colon cancers and metastases.
Materials and methods

Reovirus
The Dearing strain of reovirus serotype 3 was propagated in L929 cells grown in suspension in Joklik's modified Eagle's medium containing 5% fetal bovine serum and purified as previously reported. 4 Inactivated virus was prepared by exposing the live virus to ultraviolet (UV) light for 45 min.
AOM and reovirus treatment in Sprague-Dawley rats Female Sprague-Dawley rats were obtained from Charles River (Saint-Constant, Quebec, Canada; 150-200 g). The animals were maintained under specific pathogenfree conditions and according to a protocol approved by the University of Calgary Animal Care Committee. AOM was administered intraperitoneally (i.p.) at a dose of 15 mg/kg/week Â 4 weeks. 10 Reovirus was given starting at 20 weeks following the last dose of AOM. Reovirus was administered by rectal enemas at a dose of 1 Â 10 9 plaque-forming units (PFU) weekly for 5 weeks. Animals were killed 2 weeks later. A laparotomy was performed and animals were assessed for metastatic colon cancer. The colon and small intestine were removed, opened along the mesenteric border and examined with a stereomicroscope for any signs of tumors. The colon was then stained with 0.5% methylene blue for 5 min, rinsed in normal saline Â 3 and aberrant foci were counted using a stereomicroscope in a blinded manner. Large ACF were defined as having a diameter (41.5 mm) as measured by the stereomicroscope. Lesions larger than this were almost uniformly found to be adenocarcinoma upon histological assessment.
Development of an adenocarcinoma cell line and in vitro reovirus studies Metastatic adenocarcinoma to the liver was noted in several animals and from one animal the tumors were removed, washed in sterile phosphate-buffered saline (PBS), mechanically disrupted with surgical blades and filtered through a 100 mm nylon cell strainer to make a single-cell suspension. Single cell suspensions were plated in Dulbecco's modified Eagle medium plus 20% fetal calf serum and 2 Â antibiotics (Penicillin and Streptomycin; Sigma, Aldrich, St Louis, MO).
The metastatic adenocarcinoma cell populations were then dispensed into 12-well plates and infected with reovirus at a multiplicity of infection (MOI) of 20 PFU/ cell and assessed for cytopathic effects 48 h post-infection. For metabolic labeling, [ 35 S]methionine was added to the culture medium at designated times for a period of 6 h. Cells were harvested and lysed in PBS containing 1% Triton X-100, 0.5% sodium deoxycholate and 1 mM ethylenediaminetetraacetic acid. Lysates were cleared of debris by centrifugation and supernatants were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography and analysis for reovirus proteins l, m and s. For immunohistochemistry studies, samples infected for 48 h with reovirus at an MOI of 20 PFU/cell were fixed on slides in 10% neutral buffered formalin. Endogenous peroxidase was inactivated in 3% hydrogen peroxide in methanol for 15 min. Slides were then incubated with primary rabbit anti-reovirus polyclonal antibody (1:1000 in PBS with 10% goat serum and 0.1% Triton X-100) partially purified by ammonium sulfate precipitation. Slides were washed in PBS and then subjected to avidin-biotin-horseradish peroxidase staining as recommended by the manufacturer (Vector, Burlingame, CA) and counterstained in hematoxylin. 
Results and discussion
Reovirus rectal administration reduces AOM-induced colon carcinogenesis Reovirus type 3 Dearing selectively kills tumor cells and this oncolytic activity has now been confirmed in many different cancer cell lines, tumor xenografts and syngeneic cancer models. [3] [4] [5] 9 Such models, however, may not fully correlate with the progression of human cancer and additional models are needed to test reovirus effectiveness. AOM is a widely studied and very potent carcinogen that is known to induce CRCs at high incidence in both rats and mice. 10 The majority of in vivo animal models used to screen for preventive or therapeutic agents against different stages of colon cancer progression have involved the use of AOM-induced colon carcinogenesis because of the similarities of the disease compared to human CRC. We therefore aimed to determine the therapeutic benefit of reovirus administered rectally in immunocompetent animals exposed to the carcinogen AOM. This model allowed us to investigate the effect of reovirus against both preneoplastic lesions and late stages of colon carcinogenesis in an in vivo setting.
Female Sprague-Dawley rats were administered AOM i.p. at a dose of 15 mg/kg/week for 4 weeks. Twenty weeks later, reovirus was given rectally at a dose of 1 Â 10 9 PFU weekly for 5 weeks. Animals were killed 2 weeks later. The colon and small intestine of each animal was removed and opened along the mesenteric border and examined with a stereomicroscope for any signs of tumors. All animals developed numerous ACF and colonic carcinomas of various sizes. In addition, at the time of killing, liver and kidney metastasis was evident in all animals. Some animals had large obstructing tumors of the colon and/ or duodenum, indicative of the high carcinogenic potential of AOM.
Repeated reovirus injection once a week for 5 weeks resulted in a marked decrease in both the total number of ACF (P ¼ 0.014) and large ACF (P ¼ 0.0069) in reovirustreated animals compared to UV-inactivated reovirus (Figure 1a) . Furthermore, there was also a decrease in the numbers of colonic tumors (adenocarcinomas) (an average of 2.5 per animal or 20 in total in the control group versus 1.5 per animal or a total of 12 in the reovirus-treated group P ¼ 0.03) in the reovirus-treated animals ( Figure 1a) . Generally, the tumors in the reovirus-treated animals were smaller (Figures 1a and b) than those treated with inactivated reovirus and there was a decrease in the number of obstructing tumors noted in the duodenum (0 in the reovirus treated versus 5 (average 0.63 per animal) (P ¼ 0.03) in the control group) as well as a marginal decrease in the number of obstructing colonic tumors, although this did not achieve significance (average of 0.13 per animal (one tumor) in the reovirus group versus 0.63 per animal (five tumors) in the control group, P ¼ 0.07) (Figure 1a) . When the animals were assessed for metastatic disease, 100% of the animals had duodenal involvement in both the control and reovirustreated animals. Liver metastases were present in 100% of the animals in the control group and 87.5% in the reovirus-treated group (nonsignificant P40.05). Extensive liver metastases, defined as a single lesion larger than 1 cm in diameter and/or three separate lesions of greater than 0.5 cm, were present in 87.5% of the animals treated with inactivated virus versus 37.5% of the animals treated with live reovirus (Po0.05).
We were unable to detect reovirus proteins or RNA in the liver, duodenum or colon by immunohistochemistry and reverse transcription-PCR. We suspect this is likely due elimination of the virus by the immune system from the time of the last reovirus infusion to killing (2 weeks). However, a tumor cell line derived from a metastatic liver lesion was found to be susceptible ex vivo to reovirus oncolysis. Viral protein synthesis was evident by the presence of the reovirus proteins l, m and s measured by We conclude that reovirus delivered rectally was partially effective in the treatment and prevention of AOM-induced ACF, colon cancers and metastases. These responses were encouraging due to the extent of the cancerous lesions induced by AOM at the time of reovirus administration. It is therefore possible that therapeutic benefits of reovirus may be enhanced if administered sooner after the induction of carcinogenesis by AOM. It is known that colonic carcinomas are better treated at an early developmental stage and limited success is achieved clinically for advanced cases. Correspondingly, we observed superior therapeutic effects of reovirus on preneoplastic lesions compared to large established solid tumors. Elimination of precancerous lesions by means other than surgery/colonoscopic polypectomy may provide another avenue in the reduction or prevention of CRC incidence for individuals with increased risk of developing the disease such as patients with polyp syndromes or inflammatory bowel disease. With clinical trials using reovirus as a cancer therapeutic currently ongoing, it is important to assess different treatment modalities in immunocompetent animals, using appropriate cancer models with the goal of determining factors such as treatment duration, dose, timing of therapy and most effective mode of delivery. The present study highlights the potential role of rectal delivery of reovirus in AOMinduced colon carcinogenesis.
